Special Issue "New Advances in the Treatment of Resectable Non-small Cell Lung Cancer"
Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 16510
Interests: lung cancer; surgery; robotic surgery; minimally invasive thoracic surgery; lymphadenectomy
Interests: lung cancer surgery; biostatistics; methodology
Special Issues, Collections and Topics in MDPI journals
Despite the evolution in non-small cell lung cancer treatment, the overall prognosis is still poor. In this context, lobectomy and radical lymphadenectomy remain the cornerstone of surgical treatment of resectable NSCLC. One of the most important prognostic factors remains the presence of lymph node involvement, particularly the presence of mediastinal nodal involvement, as demonstrated in the VIII TNM staging system edition with a clear prognosis stratification considering the presence of nodal metastases. Furthermore, correct intraoperative staging is mandatory to reach an actual pathological status of the disease. The recent approval of Osimertinib for resected EGFR-mutated NSCLC in an adjuvant setting has led to the hypothesis that other targeted therapies used in metastatic patients can also lead to improved early-stage outcomes of NSCLC. Indeed, in addition to surgical treatment, some target therapies are being tested in adjuvant settings with promising outcomes. Some trials are open which use these therapies in the neoadjuvant setting. For this Special Issue, we welcome manuscripts focusing on recent advancements in the preoperative staging, the surgical resection of NSCLC, and the role of the new medications approved as adjuvant and neoadjuvant therapies. We also welcome systematic reviews, original research, economic evaluation, and cost-effectiveness studies on this relevant topic.
Dr. Francesco Facciolo
Dr. Luca Bertolaccini
Dr. Federico Cappuzzo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- early-stage NSCLC
- robotic surgery
- adjuvant therapy
- neoadjuvant therapy